文献综述

ELABELA/Apelin-APJ通路在心血管发育中作用比较

  • 杨俊婕 综述 ,
  • 孙锟 审校
展开
  • 1.温州医科大学附属第二医院育英儿童医院(浙江温州 325027)
    2.上海交通大学医学院附属新华医院小儿心血管科(上海 200092)

收稿日期: 2022-06-20

  网络出版日期: 2023-07-05

基金资助

国家自然科学基金重点项目(82130015);上海市卫健委协同创新集群项目(2020CXJQ01)

The role of ELABELA/Apelin-APJ pathway in cardiovascular development

  • YANG Junjie Reviewer: ,
  • SUN Kun Reviser:
Expand
  • 1. Yuying Children's Hospital, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang, China
    2. Department of Pediatric Cardiovascular, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

Received date: 2022-06-20

  Online published: 2023-07-05

摘要

先天性心脏病是人类最常见的出生缺陷,与胚胎期心血管发育密切相关。ELABELA/Apelin-APJ通路主要包含2个肽配体ELABELA、Apelin以及他们共同的受体APJ。已知ELABELA |Apelin-APJ通路参与了多种生理、病理过程,且与多种疾病的发生密切相关。近年来ELABELA/Apelin-APJ通路与心血管发育之间的关系得到广泛关注。文章主要针对ELABELA/Apelin-APJ通路对心血管发育强大的调控作用进行总结和比较,旨在揭示这两条通路在心脏发育的不同阶段所起的作用,以及在预防先天性心血管畸形方面的意义。

本文引用格式

杨俊婕 综述 , 孙锟 审校 . ELABELA/Apelin-APJ通路在心血管发育中作用比较[J]. 临床儿科杂志, 2023 , 41(7) : 543 -548 . DOI: 10.12372/jcp.2023.22e0853

Abstract

Congenital heart disease is the commonest birth defect and is closely related to cardiovascular development during the embryonic period. ELABELA/Apelin-APJ pathway mainly contains two peptide ligands, ELABELA and Apelin, as well as their common receptor APJ. It is known that ELABELA/Apelin-APJ pathway is involved in many physiological and pathological processes and is closely related to the occurrence of many disease. In recent years, the relationship between the ELABELA/Apelin-APJ pathway and cardiovascular development has received extensive attention. This article mainly summarizes and compares the powerful regulatory effects of the ELABELA/Apelin-APJ pathway on cardiovascular development, aiming to reveal the role of the two pathways in different stages of cardiac development and the great significance in preventing congenital cardiovascular malformation.

参考文献

[1] 高燕, 黄国英. 先天性心脏病病因及流行病学研究进展[J]. 中国循证儿科杂志, 2008, 3(3): 213-222.
[2] Zhou S, Wang J, Wang Q, et al. Essential role of the ELABELA-APJ signaling pathway in cardiovascular system development and diseases[J]. J Cardiovasc Pharmacol, 2020, 75(4): 284-291.
[3] 孟卓, 周双, 洪楠超. 小分子激素Elabela在心血管发育中的作用研究进展[J]. 中华儿科杂志, 2018, 56(12): 954-957.
[4] Wang Z, Huang J. Apela promotes cardiomyocyte differentiation from transgenic human embryonic stem cell lines[J]. Appl Biochem Biotechnol, 2019, 189(2): 396-410.
[5] Xu J, Chen L, Jiang Z, et al. Biological functions of Elabela, a novel endogenous ligand of APJ receptor[J]. J Cell Physiol, 2018, 233(9): 6472-6482.
[6] 陈海英, 高连如, 张宁坤. Apelin/APJ与胚胎心肌分化[J]. 现代生物医学进展, 2012, 12(9): 1766-1768.
[7] 蔡科, 桂永浩, 王凤. Tbx2基因调控胚胎心脏发育的研究进展[J]. 国际儿科学杂志, 2018, 45(8): 575-578.
[8] Eberlein J, Herdt L, Malchow J, et al. Molecular and cellular mechanisms of vascular development in zebrafish[J]. Life (Basel), 2021, 11(10): 1088.
[9] O’Dowd BF, Heiber M, chan A, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11[J]. Gene, 1993, 136(1-2): 355-360.
[10] Zhang Y, Wang Y, Lou Y, et al. Elabela, a newly discovered APJ ligand: similarities and differences with Apelin[J]. Peptides, 2018, 109: 23-32.
[11] Kuba K, Sato T, Imai Y, et al. Apelin and Elabela/Toddler; double ligands for APJ/Apelin receptor in heart development, physiology, and pathology[J]. Peptides, 2019, 111: 62-70.
[12] Liu W, Yan J, Pan W, et al. Apelin/Elabela-APJ: a novel therapeutic target in the cardiovascular system[J]. Ann Transl Med, 2020, 8(5): 243.
[13] Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor[J]. Biochem Biophys Res Commun, 1998, 251(2): 471-476.
[14] Yang P, Read C, Kuc RE, et al. Elabela/toddler is an endogenous agonist of the apelin APJ receptor in the adult cardiovascular system, and exogenous administration of the peptide compensates for the downregulation of its expression in pulmonary arterial hypertension[J]. Circulation, 2017, 135(12): 1160-1173.
[15] Chng SC, Ho L, Tian J, et al. ELABELA: a hormone essential for heart development signals via the apelin receptor[J]. Dev Cell, 2013, 27(6): 672-680.
[16] 章清, 瞿红鹰, 黄永顺, 等. Apelin/APJ系统在器官纤维化中研究进展[J]. 中国职业医学, 2020, 47(6): 722-727.
[17] 田艳君, 姜云璐, 韩爱忠, 等. Apelin/APJ系统及其基因多态性与心脑血管疾病的相关性[J]. 生理科学进展, 2019, 50(6): 423-428.
[18] D’Aniello C, Lonardo E, Iaconis S, et al. G protein-coupled receptor APJ and its ligand apelin act downstream of Cripto to specify embryonic stem cells toward the cardiac lineage through extracellular signal-regulated kinase/p70S6 kinase signaling pathway[J]. Circ Res, 2009, 105(3): 231-238.
[19] Ho L, Tan SY, Wee S, et al. ELABELA is an endogenous growth factor that sustains hESC self-renewal via the PI3K/AKT pathway[J]. Cell Stem Cell, 2015, 17(4): 435-447.
[20] Eberlé D, Marousez L, Hanssens S, et al. Elabela and Apelin actions in healthy and pathological pregnancies[J]. Cytokine Growth Factor Rev, 2019, 46: 45-53.
[21] Lu L, Cao J, Li L, et al. Elabela, a new endogenous ligand of APJ, functions in embryos and adults organisms[J]. Acta Biochim Biophys Sin (Shanghai), 2017, 49(4): 378-381.
[22] Helker CS, Schuermann A, Pollmann C, et al. The hormonal peptide Elabela guides angioblasts to the midline during vasculogenesis[J]. Elife, 2015, 4: e06726.
[23] Singh AM, Reynolds D, Cliff T, et al. Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation[J]. Cell Stem Cell, 2012, 10(3): 312-326.
[24] Norris ML, Pauli A, Gagnon JA, et al. Toddler signaling regulates mesodermal cell migration downstream of Nodal signaling[J]. Elife, 2017, 6: e22626.
[25] Wu L, Chen L, Li L. Apelin/APJ system: a novel promising therapy target for pathological angiogenesis[J]. Clin Chim Acta, 2017, 466: 78-84.
[26] Cox CM, D'Agostino SL, Miller MK, et al. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo[J]. Dev Biol, 2006, 296(1): 177-189.
[27] Kidoya H, Ueno M, Yamada Y, et al. Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis[J]. EMBO J, 2008, 27(3): 522-534.
[28] Scott IC, Masri B, D'Amico LA, et al. The G protein-coupled receptor Agtrl1b regulates early development of myocardial progenitors[J]. Dev Cell, 2007, 12(3): 403-413.
[29] Zeng XX, Wilm TP, Sepich DS, et al. Apelin and its receptor control heart field formation during zebrafish gastrulation[J]. Dev Cell, 2007, 12(3): 391-402.
[30] Huang Z, He L, Chen Z, et al. Targeting drugs to APJ receptor: from signaling to pathophysiological effects[J]. J Cell Physiol, 2018, 234(1): 61-74.
[31] 马秀娟, 郝晓莹. 影响胚胎血管形成的因子的研究进展[J]. 中国生育健康杂志, 2020, 31(6): 583-585.
[32] Freyer L, Hsu CW, Nowotschin S, et al. Loss of Apela peptide in mice causes low penetrance embryonic lethality and defects in early mesodermal derivatives[J]. Cell Rep, 2017, 20(9): 2116-2130.
[33] Ho L, van Dijk M, Chye STJ, et al. ELABELA deficiency promotes preeclampsia and cardiovascular malformations in mice[J]. Science, 2017, 357(6352): 707-713.
[34] Marsault E, Llorens-Cortes C, Iturrioz X, et al. The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders[J]. Ann N Y Acad Sci, 2019, 1455(1): 12-33.
文章导航

/